Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer

MLA

Robichaux, Jacqulyne P., et al. “Author Correction: Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20–selective Kinase Inhibitor in Non–small Cell Lung Cancer.” Nature Medicine, vol. 30, no. 9, Sept. 2024, pp. 2694–95. EBSCOhost, https://doi.org/10.1038/s41591-024-03178-1.

APA

Robichaux, J. P., Elamin, Y. Y., Tan, Z., Carter, B. W., Zhang, S., Liu, S., Li, S., Chen, T., Poteete, A., Estrada-Bernal, A., Le, A. T., Truini, A., Nilsson, M. B., Sun, H., Roarty, E., Goldberg, S. B., Brahmer, J. R., Altan, M., Lu, C., … Heymach, J. V. (2024). Author Correction: Mechanisms and clinical activity of an EGFR and HER2 exon 20–selective kinase inhibitor in non–small cell lung cancer. Nature Medicine, 30(9), 2694–2695. https://doi.org/10.1038/s41591-024-03178-1

Chicago

Robichaux, Jacqulyne P., Yasir Y. Elamin, Zhi Tan, Brett W. Carter, Shuxing Zhang, Shengwu Liu, Shuai Li, et al. 2024. “Author Correction: Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20–selective Kinase Inhibitor in Non–small Cell Lung Cancer.” Nature Medicine 30 (9): 2694–95. doi:10.1038/s41591-024-03178-1.